Vesugen
KED peptide, Lys-Glu-Asp, vascular bioregulator peptide
Vesugen is a three-amino-acid Khavinson peptide assigned to vascular endothelium and promoted for blood vessel health. It has around six indexed papers, all preclinical or ex vivo and all from the originating network, covering endothelial cell proliferation in ageing culture and gene expression relevant to neurogenesis. No controlled human trial exists.
Mechanism
Vesugen is assigned to vascular endothelium within the Khavinson framework, with the standard proposed mechanism of nuclear entry and direct promoter DNA interaction. The specific claim is epigenetic regulation of endothelial cell proliferation: work published in Advances in Gerontology reported that KED influences proliferative activity of vascular endothelial cells in ageing culture, framed as reversal of the replicative decline endothelium undergoes with age.
A separate line of work has examined KED in a neurological rather than vascular context. A 2021 paper in Bulletin of Experimental Biology and Medicine reported that KED modulates expression of genes involved in neurogenesis regulation with reference to Alzheimer's disease. That a peptide assigned to blood vessels is also reported to regulate neurogenesis genes is a tension in the tissue-specificity model that the literature does not address: either the organ assignments are loose, or the effects are non-specific, and both readings weaken the marketing framework.
As with the rest of the series, no receptor is proposed, no structural work demonstrates sequence-selective promoter recognition, and the concentrations at which DNA interaction has been shown in vitro exceed anything a tripeptide would plausibly achieve in tissue after administration.
What the research shows
The vascular evidence is one strand of work: a 2014 Advances in Gerontology paper on epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during ageing, reporting that KED affected endothelial proliferative capacity in culture. The 2012 tissue-specificity paper in Bulletin of Experimental Biology and Medicine included Vesugen among peptides tested in organotypic culture. The 2021 KED and neurogenesis paper extends the compound into a different domain.
Human data is effectively absent. A 2015 Russian-language paper in Advances in Gerontology reported effects of synthetic peptides on ageing in patients with chronic polymorbidity and organic brain syndrome. That study administered peptides in combination, was not controlled or blinded to any standard that permits inference, and cannot support a claim about Vesugen specifically. No registered clinical trial of Vesugen exists.
There is a broader point worth making about the vascular claim. Endothelial function is measurable in humans by well-established non-invasive methods such as flow-mediated dilation, and endothelial dysfunction is a recognised marker of cardiovascular risk. A compound claimed to restore endothelial function could be tested in a small trial with an objective endpoint relatively cheaply. That this has not been done in the two decades the compound has existed is informative.
Evidence assessment
Preclinical only
Around six indexed papers, all cell culture or ex vivo work from the originating network; the sole human report administered multiple peptides together without controls and permits no compound-specific inference.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging Preclinical only
KED was reported to influence proliferative activity of ageing vascular endothelial cells, framed as epigenetic regulation.
Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease Preclinical only
KED was reported to modulate expression of genes involved in neurogenesis regulation relevant to Alzheimer's disease pathogenesis.
Peptides tissue-specifically stimulate cell differentiation during their aging Preclinical only
Reported tissue-preferential stimulation of differentiation in ageing cultures.
Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission Limited evidence
Reported effects on ageing markers in patients with chronic multi-morbidity.
Safety
No formal safety characterisation. No toxicology, no animal safety study, no human adverse event record, no dose-ranging. Absence of reported harm reflects absence of systematic investigation. Material sold online is unregulated and its identity, purity, sterility and endotoxin content are unverified.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA, never studied under an investigational new drug application, absent from clinical trial registries. Sold as a research chemical. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
There is no controlled human evidence. The vascular claim rests on cell culture work reporting effects on endothelial proliferation in ageing cultures. Endothelial function is measurable non-invasively in humans, so the absence of such a study after two decades is itself notable.
The one-letter code for the sequence lysine, glutamate, aspartate. Vesugen is a tripeptide, one of the shortest compounds in the Khavinson series.
A 2021 paper reported that KED modulates neurogenesis-related gene expression. This sits uneasily with the claim that each peptide targets one organ: either the assignments are loose or the effects are non-specific, and neither reading supports the marketing framework.
No registered clinical trial exists. The one human paper administered several peptides together in an uncontrolled setting, so no effect can be attributed to Vesugen specifically.